Kornimate/medical-research-clean huggingface dataset:
lovaza mechanisms of action

Conditions: Moderate Hypertriglyceridemia.

Summary: high levels of triglycerides is a common abnormality found in patients with diabetes and also cardiovascular disease, and may contribute to the risk for both. omega 3 fatty acids, as found enriched in fish and also in the commercial agent called lovaza lower triglyceride levels. prior work from the investigators group demonstrated that an enzyme responsible for the break down of triglycerides - lipoprotein lipase - generates molecules that can activate a specific nuclear receptor known as ppar-alpha. this study investigates the hypothesis that taking lovaza shifts the specific fatty acid content of triglyceride containing lipoproteins and increases the ability of those lipoproteins to activate ppar-alpha.

this study will investigate changes in lipid and other metabolic parameters as well as the ability of isolated lipoproteins to activate ppars in the presence or absence of lipoprotein lipase in a cohort of normal healthy individuals with modest hypertriglyceridemia before and after a course of lovaza.

Eligibility criteria:
inclusion criteria: * otherwise healthy 21 to 65 year old men and women * triglycerides \>150 \< 500 mg/dl exclusion criteria: * other lipid lowering medication including fish oil * major illnesses * diabetes * cardiovascular disease * abnormalities uncovered on screening blood work including undiagnosed diabetes, abnormal liver function tests, triglycerides \> 500 mg/dl * indication for immediate statin therapy * pregnancy * contraindication for fish oil use or muscle biopsy

Keywords: hypertriglyceridemia fish oil omega 3 fatty acids
open pilot trial of a mind-body program for cardiac arrest survivors and their caregivers

Conditions: Emotional Distress; Cardiac Arrest

Summary: the purpose of this study is to pilot a mind-body intervention for cardiac arrest survivors and their informal caregivers, recovering together after cardiac arrest. the data the investigators gather in this study will be used to further refine our intervention.

the goal of this study is to refine our proposed intervention recovering together after cardiac arrest (rt-ca) through an open pilot. the investigators will deliver an open pilot of the intervention (n=5 dyads; 10 participants total) to evaluate initial feasibility and acceptability using exit interviews and pre-post assessments. the open pilot will take place at massachusetts general hospital intensive care units and step-down units. study clinicians will deliver 6, 30 minute sessions of the intervention (at bedside or on zoom/telephone, depending on participant preference and access). all participants will complete measures at baseline, and after completion of program (6 weeks). at the completion of the program, participants will engage in an exit interview where they will provide feedback of the intervention.

Eligibility criteria:
inclusion criteria: 1. out-of-hospital or in-hospital ca survivor (must have new diagnosis of "cardiac arrest" in electronic medical record from index hospitalization with documented loss of pulse) with an identified caregiver (identified by the survivor who is their primary source of emotional and functional support) 2. score ≥4 on short form of the mini mental state exam 3. ability and willingness to participate in a hybrid in-person/live video or phone intervention 4. english speaking adults, 18 years or older 5. at least one member of the dyad endorses clinically significant emotional distress during screening (\>7 on hospital anxiety and depression scale subscales) exclusion criteria: 1. active psychosis, mania, substance dependence, or suicidal intent or plan
prospective study for neuromelanin image analysis

Conditions: Parkinson Disease

Summary: in order to develop an image analysis system that automatically detects and quantifies neuromelanin, this study aims to construct a database of a wide sample by collecting brain mri neuromelanin images prospectively.


Eligibility criteria:
parkinsin group inclusion criteria: * adults over 19 years old * those who have clinically shown parkinson's symptoms such as tremor, rigidity, bradykinesa and gait disturbance and are scheduled to take mri scans * dopamine transporter imaging shows a significant decrease in visual dopamine intake * a person who can read and understand the description and informed consent form * upon hearing and fully understanding the detailed explanation of this clinical trial, a person who has voluntarily decided to participate and agreed in writing to comply with the precautions exclusion criteria: * patient with a history of claustrophobia and mental illness; * patient with metallic substances in the body * any female subject who is likely to be pregnant who does not agree to contraception in a medically permitted manner during this clinical trial period * pregnant or lactating women * other cases where the investigator judged that it is difficult to participate in the study; healthy volunteer group inclusion criteria: * adults over 19 years old * a person who has no family history or diagnostic history of movement disorders; * a person with a score of 8 or higher on the ccsit(cross cultural smell identification test) * a person with a score of 27 or higher on the mmse test * no parkinson's symptoms on a neurological examination * upon hearing and fully understanding the detailed explanation of this clinical trial, a person who has voluntarily decided to participate and agreed in writing to comply with the precautions exclusion criteria: * patient with a history of central nervous system disease or cognitive disorder * patient with a history of claustrophobia and mental illness; * patient with metallic substances in the body * any female subject who is likely to be pregnant who does not agree to contraception in a medically permitted manner during this clinical trial period * pregnant or lactating women * other cases where the investigator judged that it is difficult to participate in the study;
four-week study of the safety and efficacy of nls-2 (mazindol extended release) in the treatment of narcolepsy

Conditions: Narcolepsy; Excessive Daytime Sleepiness; Cataplexy Narcolepsy

Summary: this is a double-blind, randomized, placebo-controlled, multicenter trial of nls-2 in adult patients with narcolepsy. the study will enroll approximately 60 patients and eligible patients will be treated to receive either nls-2 or placebo for 4-weeks.


Eligibility criteria:
key inclusion criteria: * males and females between 18 and 65 years of age, inclusive * diagnosis of narcolepsy according to icsd-3 (international classification of sleep disorders, 3rd edition) or diagnostic and statistical manual of mental disorders, 5th edition (dsm-5) criteria * body mass index from 18 to 40 kg/m2, inclusive * consent to use a medically acceptable method of contraception * willing and able to provide written informed consent key exclusion criteria: * female subjects who are pregnant, nursing, or lactating * any other clinically relevant medical, behavioral, or psychiatric disorder other than narcolepsy that is associated with excessive sleepiness * history or presence of bipolar disorder, bipolar related disorders, schizophrenia, schizophrenia spectrum disorders, or other psychotic disorders according to dsm-5 criteria * use of any over-the-counter (otc) or prescription medications that could affect the evaluation of excessive sleepiness * use of any medications that could affect the evaluation of cataplexy * received an investigational drug in the past 30 days or five half-lives (whichever is longer)
solifenacin as add-on therapy for overactive bladder symptoms in men treated for benign prostatic hyperplasia

Conditions: Benign Prostatic Hyperplasia; Benign Prostatic Hypertrophy; Overactive Bladder

Summary: to evaluate the efficacy and safety of solifenacin succinate as add-on therapy for overactive bladder (oab) symptoms in men who have been treated for benign prostatic hyperplasia (bph) with tamsulosin hydrochloride for at least 6 weeks

study drugs are administered for 14 weeks in total, including a 2-week run-in period (single blind) and a 12-week treatment period (double blind). after written informed consent, study drugs for the run-in period are orally administered once daily after breakfast for two weeks to subjects who fulfill the inclusion and exclusion criteria. then, subjects are randomized and orally treated with study drugs for the treatment period once daily after breakfast for 12 weeks

Eligibility criteria:
inclusion criteria: * patients with benign prostatic hypertrophy who have been treated with tamsulosin for at least 6 weeks * patients with urgency episodes and frequent micturitions * written informed consent has been obtained * uroflowmetry-q max ≥ 5 ml/sec, and post void residual volume \< 50 ml exclusion criteria: * patients with suspected symptoms of oab whose onset is only transient (drug-induced, psychogenic, etc.) * patients with obvious stress urinary incontinence * patients with complications or who have a past history of a bladder tumor * patients with urethral stricture or bladder neck stenosis * patients with a history of surgery causing damage to the pelvic plexus * patients with history of hypersensitivity to α receptor blockers, a/b receptor blockers, or anticholinergic drugs * patients with orthostatic hypotension, ulcerative colitis, hyperthyroidism, dementia or cognitive dysfunction, parkinson's disease, or cerebrovascular disorder

Keywords: vesicare solifenacin succinate tamsulosin overactive bladder bph
effect of kinesiotaping for the treatment of hormone-induced myalgia in women given breast cancer survivors

Conditions: Breast Neoplasms

Summary: background: it has been demonstrated that aromatase inhibitors (ais) are more effective than tamoxifen in reducing breast cancer recurrence. however, despite the excellent results, the side effects associated with them cause between 24.5 and 31.3% therapy abandon. this study aimed to verify the effectiveness of neuromuscular taping (nmt) in the treatment of myalgia and arthralgia induced by ais in women who have had breast cancer. our goal is to improve their pain, decreasing by 20% the values of their visual analogue scale (vas) at various points in order to improve symptoms and increase adherence. methods/design: the study includes 156 breast cancer survivors treated with endocrine therapy (aromatase inhibitors or tamoxifen and aromatase inhibitors) from virgen de la victoria hospital (málaga, spain) and musculoskeletal disorders resulting from such treatment. clinical and patient data were obtained from medical histories, genetic and proteomic analysis, grip strength and algometry measured, questionnaires and the outcome of interest, their vas. nmt is applied in four possible locations, according to the symptoms of each participant: carpal tunnel, cervical, lumbar or lumbar and cervical. there are several more interventions before repeating the readings from the last five weeks of the start of the study.


Eligibility criteria:
inclusion criteria: * to be of legal age * having suffered from primary breast cancer with histological confirmation (i-iiia) * completion of primary carcinoma treatment (surgery, chemotherapy, radiotherapy) * to be receiving hormone therapy as an adjunct to the process by aromatase inhibitors (exemestane, anastrozole, letrozole) * to present a functional status according to who from 0 (asymptomatic, complete and ambulatory activity) or 1 (symptomatic but completely ambulatory, strenuous physical activity restricted but able to perform sedentary gentle activities) * to understand correctly spanish * to show their approval by signing the informed consent * having had musculoskeletal disorders attributable to ia.

Keywords: breast cancer hormonal therapy aromatase inhibitors estrogen deprivation myalgia arthralgia carpal tunnel syndrome pressure pain threshold neuromuscular taping kinesio taping
home vision monitoring using the foreseehome device following treatment of neovascular age related macular degeneration

Conditions: Age Related Macular Degeneration; Choroidal Neovascularization

Summary: foreseehome, an fda-approved home device, was specifically designed for unsupervised preferential-hyperacuity-perimeter (php) testing of age related macular degeneration (amd) patients at home by characterizing central and paracentral metamorphopsia . the purpose of the current study is to evaluate if, in post-treatment patients, php parameters as measured with the foreseehome are in agreement with clinical decisions and retinal characteristics as measured with optical coherence tomography (oct).


Eligibility criteria:
inclusion criteria: 1. received intravitreal antiangiogenic therapy for cnv in the study eye (se), within 2-12 months prior to the study 2. last diagnosis was, and current diagnosis is, no cnv activity in se eye 3. current plan in se is clinical examination as standard care but at intervals of not more than 8 weeks. 4. visual acuity of 20/80 or better in se 5. are capable and agree to sign a consent form and participate in the study 6. age \> 55 year of age 7. are able to use a standard computer mouse correctly and without assistance 8. have a working telephone landline at the main residence (cellular communication maybe available for the study, and then eliminate this requirement) 9. clear view of the macular area on fundus photography 10. are willing to give their name and contact information to notal vision, supplier of the device, so that the company can provide direct services if needed (e.g., assist in using the home device, report the frequency of usage, coordinate replacement of devices in case of a technical problems, etc.) 11. agree to be examined by an ophthalmologist if se shows symptoms of changes during the study 12. have a us address and do not plan on traveling abroad during the study period 13. fluent in english 14. perform a reliable foreseehome test during the enrollment visit exclusion criteria: 1. evidence of macular disease other than amd or glaucoma in se 2. presence of any significant media opacity that precludes a clear view of the macular area as identified in se by biomicroscopy 3. any non-macular related ocular surgery performed within 3 months prior to study entry in se 4. participant are not enrolled in another stuy that could affect the interval between clinical examinations, or the frequency of use of the foreseehome device

Keywords: cnv amd
neoadjuvant chemotherapy plus/minus surgery in non-small-cell lung cancer (nsclc) stage iiia/n2

Conditions: Non-Small Cell Lung Cancer

Summary: hypothesis is that surgery is of benefit in locally advanced nsclc with n2 disease. patients are randomised to surgery or not.

patients are after staging randomised to neoadj. chemotherapy followed by surgery followed by irradiation or to chemotherapy followed by irradiation. endpoint is survival.

Eligibility criteria:
inclusion criteria: * histologically verified nsclc * stage iiia/n2 * age 18-75 * lung function test allowing surgery * mediastinoscopy performed exclusion criteria: * prior chemotherapy * prior irradiation

Keywords: n2 disease non-small cell lung cancer surgery neoadjuvant chemotherapy
very thin stents for patients with left main or bifurcation in real life: the rain a multicenter study

Conditions: Stent Restenosis; Stent Thrombosis; Left Main Coronary Artery Disease; Coronary Bifurcations; Very Thin Stents

Summary: for permanent coronary stents, reduction of thickness of struts have become one of the most important innovation, being related to easier manipulation, reduced risk of stent thrombosis and low rate of revascularization. consequently the investigators performed a multicenter registry enrolling all consecutive patients treated with very thin stents for ulm or bifurcation.

for permanent coronary stents, reduction of thickness of struts have become one of the most important innovation, being related to easier manipulation, reduced risk of stent thrombosis and low rate of revascularization. previous studies do not have enough power to detect potential significant difference for ulm or bifurcation lesions. consequently the investigators performed a multicenter registry enrolling all consecutive patients treated with biomatrix flex, xience alpine, ultimaster, resolute onyx and synergy. mace (a composite end point of death, myocardial infarction, target lesion revascularization and stent thrombosis) will be the primary end point, while its single components will be the secondary ones.

Eligibility criteria:
inclusion criteria: * patients undergoing pci on unprotected left main or coronary bifurcation exclusion criteria: * pci performed on other coronary vessels
impact of steroid, diuretic, and fluid use on bpd outcomes

Conditions: BPD - Bronchopulmonary Dysplasia

Summary: assess the impact of steroid, diuretic, and fluid practices on bpd outcomes in extreme premature infants in the banner - university medical center phoenix (bumcp) neonatal intensive care unit (nicu).

the investigators propose performing a retrospective analysis of the current respiratory management methods to potentially find a correlation between the number of steroid doses administered, the timing of initiation of steroid therapy and the effect on premature infants at risk for developing bpd. the investigators are also going to explore the number and timing of diuretic medications and average fluid intake.

Eligibility criteria:
inclusion criteria: * infants born at \<30 weeks and/or \<1500g * admitted to bumcp between january 1, 2019 and december 31, 2020 exclusion criteria: * infants that do not survive to 36 weeks cga, when the determination of bpd is made * infants that are transferred to another hospital prior to 36 weeks cga * out born infants * infants with life threatening congenital anomalies * investigator discretion as to other factors which might impact the study
a clinical study to evaluate ospemifene in the treatment of vulvar and vaginal atrophy in postmenopausal women

Conditions: Atrophy; Vaginal Diseases

Summary: the purpose of this study is to determine whether ospemifene is more effective than placebo in the treatment of vulvar and vaginal atrophy (vva) in postmenopausal women.


Eligibility criteria:
inclusion criteria: * naturally or surgically postmenopausal * moderate or severe symptoms of vaginal atrophy (ie, vaginal dryness, irritation or itching, difficult or painful urination, pain or bleeding with intercourse) * vaginal ph greater than 5.0 * 5% or fewer superficial cells in maturation index of vaginal smear exclusion criteria: * evidence of endometrial hyperplasia, endometrial cancer, or other abnormal endometrial pathology * abnormal pap smear * uterine bleeding of unknown origin or uterine polyps * current vaginal infection requiring medication

Keywords: urogenital atrophy vaginal atrophy vulvar and vaginal atrophy in postmenopausal women menopausal symptoms
tese and non obstructive azoospermia

Conditions: Azoospermia, Nonobstructive

Summary: azoospermia is complete absence of sperm in the ejaculate. it accounts for 10-15% of male infertility cases. it is classified as obstructive and non-obstructive azoospermia (noa). noa constitutes 60% of all cases of azoospermia. testicular sperm extraction (tese) for intracytoplas¬mic sperm injection (icsi) was first introduced for treatment of obstructive azoospermia in 1993. soon afterwards testicular sperm were retrieved successfully and used in icsi in cases of noa. in the noa cases, tese combined with icsi has been proven to be an acceptable line of treatment. microdissection tese may have some theoretical benefits over conventional tese, but uncertainty exists about its superiority. during a conventional tese procedure, the testis is exposed through a small incision and one or multiple biopsies are taken blindly. micro tese was first introduced in 1999. in this technique, the tunica albuginea is widely opened and examination of the testicular tissue is carried out at 20-25× magnification under an operating microscope allowing visualization of whitish, larger and more opaque tubuli. the concept of this technique is that these tubuli are more likely to contain active spermatogenesis. also no secure clinical predictors of (sr) are demonstrated for both procedures.the recovery of spermatozoa is successful in only 50% of cases and therefore the ability to predict those patients with a high probability of achieving a successful sperm retrieval would be of great value in counselling the patient and his partner . there is no single clinical finding or investigation that can accurately predict the outcome of tese.an unsuccessful sperm recovery has important emotional and financial implications so objective counselling based on predictive factors may offer realistic expectations for both the couple and physician.

in assiut university

Eligibility criteria:
inclusion criteria: * all infertile males with non-obstructive azoospermia exclusion criteria: * patient with obstructive azoospermia: * normal fsh * dilated seminal vesicle or ejaculatory duct

Keywords: tese sperm retreival azoospermia fsh lh
study of factors influencing post-stroke dementia

Conditions: Cerebrovascular Disorders; Dementia

Summary: if the risk of dementia occurrence after stroke is well known, few data exist about the factors influencing positively or negatively the developement of cognitive disorders or dementia. the aim of the study is so to determine prospectively the clinical, biological, lesional and pharmacological factors associated with post-stroke dementia by the long-term follow-up of a stroke patient cohort.

the strokdem study is based on the 5-year prospective follow-up of a population of 1100 stroke patients without dementia. at inclusion in the cohort, main antecedents and risk factors, previous treatment and lifestyle, initial severity and etiology are recorded. biological samples (for standard ans specialized analyses) and mri are performed at 72h after stroke occurrence. thereafter, patients are regularly (6 months, 12 months, 36 months, 60 months) examined for clinical and cognitive assessment with biological samples and magnetic resonance imaging. patients with dementia will be compared to patients without stroke to identify, by logistic regression analysis and cox model, the factors associated with dementia occurrence.

Eligibility criteria:
inclusion criteria: * patients \> 40 years olds * hemispheric stroke * stroke dating from less 72h * iq-code \< 64 * patient (or his family) given an informed consent exclusion criteria: * non hemispheric stroke * malformative intracranial hemorrhage * traumatic intracranial hemorrhage * subarachnoidal hemorrhage * contra-indication to mri * patients unable to answer to cognitive battery

Keywords: stroke brain ischemia intracranial hemorrhage dementia, vascular alzheimer's disease